Jeanette M. Bjorkquist, Principal Financial Officer and Principal Accounting Officer of Assembly Biosciences, Inc. (NASDAQ:ASMB), filed a Form 4 on November 3, 2026, disclosing a performance-based restricted stock unit vesting event on October 30, 2026, and two sell-to-cover share sales on November 2, 2026.

Key Highlights

  • Performance vesting achieved: 3,840 shares of common stock were acquired on October 30, 2026 at $0, following the achievement of a performance-based vesting condition under an RSU award originally dated June 16, 2025.
  • Sell-to-cover transaction: 718 shares were sold on November 2, 2026 at a weighted average price of $19.6077, with individual sale prices ranging from $19.28 to $20.27, inclusive.
  • Second sell-to-cover tranche: An additional 9 shares were sold on November 2, 2026 at a weighted average price of $20.348, with individual sale prices ranging from $20.30 to $20.37, inclusive.
  • Remaining beneficial ownership: Following all reported transactions, Bjorkquist directly held 17,673 shares of common stock.
  • Mandatory sales: According to the filing, the sales were "mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors" and "do not represent discretionary transactions by the reporting person."
  • Future vesting: The filing notes that the award vests in two equal installments, with the second installment scheduled for October 30, 2027, subject to continuous service.

Bjorkquist RSU Vesting and Tax-Withholding Sales at Assembly Biosciences

According to the filing, Jeanette M. Bjorkquist, serving as Principal Financial Officer and Principal Accounting Officer at Assembly Biosciences, Inc., acquired 3,840 shares of common stock on October 30, 2026, at a price of $0. The filing states these shares are "issuable under a performance-based restricted stock unit award dated June 16, 2025" and that "on October 30, 2026, the performance-based vesting condition was achieved." The award vests in two equal installments on October 30, 2026 and October 30, 2027, assuming continuous service on each vesting date.

On November 2, 2026, the filing reports two separate share sales. The first involved 718 shares sold at a weighted average price of $19.6077, in multiple transactions at prices ranging from $19.28 to $20.27, inclusive. The second involved 9 shares sold at a weighted average price of $20.348, in multiple transactions at prices ranging from $20.30 to $20.37, inclusive. The filing attributes both sales to a Compensation Committee administrative rule requiring tax withholding obligations to be funded through a "sell-to-cover" transaction, describing them as non-discretionary.

Prior to the reported transactions, the filing implies a beginning direct holding that, after adding 3,840 acquired shares and subtracting 727 total shares sold, resulted in a final direct beneficial ownership of 17,673 shares. The Form 4 was signed by John O. Gunderson as Attorney-in-Fact and filed on November 3, 2026.

What Was Disclosed

The filing disclosed a performance-based RSU vesting of 3,840 shares at $0 on October 30, 2026, followed by two mandatory sell-to-cover sales totaling 727 shares on November 2, 2026, leaving Bjorkquist with a direct beneficial ownership of 17,673 shares of Assembly Biosciences common stock.